AIDX
20/20 Biolabs, Inc. Common StockNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$15.93M
P/E Ratio
—
EPS
$-0.36
Beta
-0.42
52W High
$50.00
52W Low
$1.45
50-Day MA
$2.47
200-Day MA
$3.12
Dividend Yield
—
Profit Margin
-182.80%
Forward P/E
—
PEG Ratio
—
About 20/20 Biolabs, Inc. Common Stock
20/20 Biolabs, Inc. (ticker: AIDX) is a forward-thinking biotechnology company dedicated to advancing genomic research and diagnostics through innovative laboratory services. By focusing on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is at the forefront of molecular diagnostics. With a strong commitment to harnessing cutting-edge technologies, 20/20 Biolabs is well-positioned to lead the charge in personalized medicine as the demand for genomic data accelerates. The company’s strategic initiatives and robust market positioning signal a promising growth trajectory in the dynamic biotechnology sector.
Fundamentals
| Revenue (TTM) | $2.05M |
| Gross Profit (TTM) | 604,540 |
| EBITDA | $-3.25M |
| Operating Margin | -169.60% |
| Return on Equity | -503.00% |
| Return on Assets | -53.90% |
| Revenue/Share (TTM) | $0.41 |
| Book Value | $-0.01 |
| Price-to-Book | 317.43 |
| Price-to-Sales (TTM) | 7.79 |
| EV/Revenue | 8.1 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.40% |
| Shares Outstanding | $10.48M |
| Float | $9.02M |
| % Insiders | 35.17% |
| % Institutions | 0.00% |
More HEALTHCARE Stocks
Data last updated: 5/5/2026